Mizuho lowered the firm’s price target on Nkarta (NKTX) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report. It moderated the near-term ramp and unadjusted peak sales for NKX019, citing the current competitive landscape in autoimmune diseases.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
- Nkarta Announces Leadership Change with New CMO
- Nkarta appoints Shawn Rose as CMO, head of R&D
- Nkarta’s Strategic Enhancements in NKX019 Program and Trial Expansion Drive Positive Buy Rating
- Nkarta, Inc. Reports Q1 2025 Financial Results